ATE440604T1 - Verfahren zum evaluieren und behandeln von krebs - Google Patents

Verfahren zum evaluieren und behandeln von krebs

Info

Publication number
ATE440604T1
ATE440604T1 AT05254157T AT05254157T ATE440604T1 AT E440604 T1 ATE440604 T1 AT E440604T1 AT 05254157 T AT05254157 T AT 05254157T AT 05254157 T AT05254157 T AT 05254157T AT E440604 T1 ATE440604 T1 AT E440604T1
Authority
AT
Austria
Prior art keywords
cancer
evaluation
treatment
Prior art date
Application number
AT05254157T
Other languages
English (en)
Inventor
Mitch Raponi
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Application granted granted Critical
Publication of ATE440604T1 publication Critical patent/ATE440604T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT05254157T 2004-07-01 2005-07-01 Verfahren zum evaluieren und behandeln von krebs ATE440604T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/883,436 US20050003422A1 (en) 2003-07-01 2004-07-01 Methods for assessing and treating cancer

Publications (1)

Publication Number Publication Date
ATE440604T1 true ATE440604T1 (de) 2009-09-15

Family

ID=35058443

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05254157T ATE440604T1 (de) 2004-07-01 2005-07-01 Verfahren zum evaluieren und behandeln von krebs

Country Status (14)

Country Link
US (1) US20050003422A1 (de)
EP (1) EP1611890B1 (de)
JP (1) JP2006014739A (de)
KR (1) KR20060048684A (de)
CN (1) CN1721553A (de)
AR (1) AR049564A1 (de)
AT (1) ATE440604T1 (de)
AU (1) AU2005202520A1 (de)
BR (1) BRPI0502433A (de)
CA (1) CA2512493A1 (de)
DE (1) DE602005016189D1 (de)
DK (1) DK1611890T3 (de)
MX (1) MXPA05007207A (de)
PT (1) PT1611890E (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR048945A1 (es) * 2004-05-06 2006-06-14 Veridex Llc Pronostico para leucemia mieloide cronica
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
CN102317772A (zh) * 2007-03-12 2012-01-11 维里德克斯有限责任公司 测定急性髓性白血病对用法尼基转移酶治疗的反应的方法
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8296867B2 (en) * 2008-03-21 2012-10-30 Bauer Hockey, Inc. Helmet for a hockey or lacrosse player
CA2751888C (en) * 2009-02-11 2022-06-14 Caris Mpi, Inc. Molecular profiling of tumors
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
CA2806112C (en) * 2010-07-28 2023-03-21 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
WO2017184968A1 (en) * 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es) * 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US20210231666A1 (en) * 2018-06-06 2021-07-29 La Jolla Institute For Immunology Cd33 monocytes as a biomarker

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
EE03484B1 (et) 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
ATE252104T1 (de) 1996-12-20 2003-11-15 Tovarischestvo S Ogranichennoi Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12- lid- hydrochlorid
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
JP2005522990A (ja) * 2001-10-30 2005-08-04 オルソ−クリニカル ダイアグノスティクス,インコーポレイティド 白血病の評価及び処理方法
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
EP1502962A3 (de) * 2003-07-01 2006-01-11 Veridex, LLC Methoden zur Einschätzung und zur Behandlung von Krebserkrankungen

Also Published As

Publication number Publication date
EP1611890A1 (de) 2006-01-04
CA2512493A1 (en) 2006-01-01
DK1611890T3 (da) 2009-11-16
DE602005016189D1 (de) 2009-10-08
AU2005202520A1 (en) 2006-01-19
JP2006014739A (ja) 2006-01-19
AR049564A1 (es) 2006-08-16
KR20060048684A (ko) 2006-05-18
MXPA05007207A (es) 2006-05-22
PT1611890E (pt) 2009-09-29
US20050003422A1 (en) 2005-01-06
CN1721553A (zh) 2006-01-18
EP1611890B1 (de) 2009-08-26
BRPI0502433A (pt) 2006-04-04

Similar Documents

Publication Publication Date Title
EP1989308A4 (de) Verfahren und zusammensetzungen zum behandeln und erkennen von missgefaltetem sod1-herbeigeführte erkrankungen
DE602007006479D1 (de) Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen
EP1793745A4 (de) Verfahren und vorrichtungen zum greifen und bewerten von gewebe
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE602005004280D1 (de) Verfahren zum ziehen von sic-einkristallen und sic-einkristall
DE602007012538D1 (de) Verfahren und Vorrichtung zur Durchführung delegierter Transaktionen
DE602006012823D1 (de) Vorrichtung und verfahren zum neusynthetisieren von signalen
EP2049140A4 (de) Kit und verfahren zur behandlung der bandscheiben
DE112008003045A5 (de) Verfahren und Vorrichtung zum Behandeln von Schlamm
DE602005017318D1 (de) Verfahren und Vorrichtung zum Bereitstellen von Entwurfsdaten
DE602005012917D1 (de) Verfahren und Vorrichtung zum Umformen
DE602006019769D1 (de) Verfahren und gerät zum falten von artikeln
DE602005000515D1 (de) Reissverschluss und Verfahren zum Herstellen desselben
EP1786465A4 (de) Verfahren zur detektion und behandlung von autoimmunstörungen
EP1948675A4 (de) Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
DE602006009890D1 (de) Verfahren zum Hinzufügen eines Effekts und Vorrichtung zum Hinzufügen eines Effekts
DE602005016189D1 (de) Verfahren zum Evaluieren und Behandeln von Krebs
DE602005017898D1 (de) Verfahren und kit zum nachweis von histamin
AT504810A3 (de) Vorrichtung und verfahren zum herstellen von pastillen
EP1848834A4 (de) Verfahren zur behandlung von kupferhaltigen materialien
DE102005033305A8 (de) Werkzeug und Verfahren zum Bearbeiten von Geröll
ATE508984T2 (de) Chemisches verfahren und vorrichtung
ATE393388T1 (de) Verfahren zum detektieren und entfernen von fremdkörpern
DE112007002256A5 (de) Heizvorrichtung und Verfahren zum Heizen von Gegenständen
DE602004014412D1 (de) Verfahren und vorrichtung zum programmieren eines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties